To screen for cystic fibrosis (CF) in newborn infants
Immunoreactive Trypsin
As part of a newborn screening test
A blood sample taken from an infant’s heel, a spot of blood that is put onto filter paper
None
-
How is it used?
Immunoreactive trypsin (IRT) is used to screen for cystic fibrosis (CF) in new-born infants. In the UK, it is now part of the routine neonatal screening programme.
-
When is it requested?
This test is used as part of a newborn screen for cystic fibrosis (CF) in all babies in the UK.
IRT testing can not detect all cases of cystic fibrosis (CF) and a positive test can be due to diseases other than CF and other diseases of the pancreas can cause a positive IRT. An elevated level must be followed with other testing. When diagnosing CF this may include: another IRT measurement around 4 weeks later, CF gene mutation testing, and/or sweat chloride testing.
-
What does the test result mean?
If an IRT level is elevated, a baby may have cystic fibrosis or the elevated IRT may be a false positive result. Elevated levels need to be followed with further testing. If the IRT level is negative but the baby has symptoms, other testing for CF such as sweat chloride and/or CF gene mutation testing may be considered.
-
Is there anything else I should know?
IRT testing will not identify CF carriers. Their trypsinogen production and function will not be affected. In patients who do have CF, the level of the IRT elevation does not indicate how bad the disease is.
-
What other tests might my doctor do to check for pancreas function?
Your doctor may request a blood test for amylase, lipase, insulin and c-peptide or HbA1c and faecal elastase to look at other aspects of pancreas and digestive function. IRT can detect pancreatitis at any age but is not routinely used in the UK for this purpose and is not better than amylase or lipase.